

OVERVIEW

- Developing novel uses and delivery forms of drugs for infectious diseases, rare disorders, mental health
- Advancing clinical development of Bucillamine for infectious diseases (COVID-19) and ischemia reperfusion
- Novel uses and delivery (Thin film, Patch) of Psilocybin
- Robust patent portfolio ([15 patents and patent applications](#))
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine <i>(Intravenous)</i>	Rare Inflammatory Disorders Ischemia-reperfusion	Phase 1/2	IND filing for clinical study
Oral Psilocybin <i>(Oral Capsule)</i>	Substance Use Disorder Methamphetamine	Phase 1/2	CTA with University of Wisconsin
Psilocybin <i>(Oral Thin Film, Microneedle Patch)</i>	Mental Illness Depression, Anxiety	IND-enabling	Target FDA IND Approval

STRATEGIC PARTNERS



EXPECTED MILESTONES 2H-2023

- ▶ Complete reformulation of Bucillamine IV for future studies in infectious diseases and ischemia-reperfusion
- ▶ IND-enabling studies of Psilocybin Patch
- ▶ Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ Psilocybin oral thin film strip development
- ▶ MDMA patch for research purposes

TEAM

Management

Michael Frank, Chairman & CEO
 Carmelo Marrelli, CFO
 Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO
 Dr. Arshi Kizilbash, M.D.
 Dr. Osnesmo Mpanju, Regulatory Affairs
 Dr. John Fahy, MD, Clinical and Scientific Advisor

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
 82 Richmond Street East
 Toronto, ON M5C 1P1

Tel: 1-888-901-0036
 E-mail: info@revivether.com
 Website: revivether.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.035 (July 20, 2023)
52-week High / Low:	CAD \$0.485 / \$0.02
Shares Outstanding:	356,237,674
Market Cap:	CAD ~ 12,500,000